Kornimate/medical-research-clean huggingface dataset:
bleb function and morphology with intratendon injection of mmc compared with standard method

Conditions: Glaucoma

Summary: patients with advanced glaucoma that are candidates for trabeculectomy will be included. thorough ophthalmic examination including best corrected visual acuity, slit lamp examination, intraocular pressure (iop) measurement, gonioscopy, funduscopy and specularly microscopy will be performed for all participants. patients will be assigned randomly to 2 groups. in one group they will undergo fornix based trabeculectomy with conventional mmc 0.02% soaked sponges application. in the other group 0.1 cc of 0.01 mmc will be injected into the tenon at the beginning of the surgery. the rest of the operation is the same for both groups as standard trabeculectomy. ophthalmic examination including iop measurement will be performed at one, 3 and 6th month post surgery. specular microscopy will be requested at final follow up visit. bleb morphology will be scored according to indian grading system at 3rd and 6th months post surgery.


Eligibility criteria:
inclusion criteria: * advanced uncontrolled glaucoma patients. exclusion criteria: * history of any kind of intraocular surgery. * monocular patients. * unwillingness to participate in the study
tace combined with lenvatinib and pd-1 inhibitor for ruptured hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Transcatheter Arterial Chemoembolization; Anti-PD1 Antibody; Lenvatinib

Summary: hepatocellular carcinoma (hcc) with spontaneous rupture is a potentially fatal complication and usually has poor prognosis. in most conditions, the tumors could not be radically moved. then minimally therapy like transcatheter arterial chemoembolization (tace) could effectively stanch the ruptured tumor and bleeding vessels. then tace combined the lenvatinib and pd-1 inhibitor for this subtype hcc could effectively inhibit the tumor and improve the prognosis.

spontaneous rupture of hcc is a life-threatening complication. hcc rupture is considerably higher in china. the tumor size in ruptured hcc is significantly greater than that in non-ruptured hcc. in the acute phase, hemostasis is the first concern and then tumor treatment is secondary. tace can effectively induce hemostasis. conservative treatment is usually system therapy for unresectable ruptured hcc. thus, we conduct this multicenter single arm study to explore the efficacy, safety of tace combined lenvatinib and pd-1 inhibitor for unresectable ruptured hcc. this study focuses on the efficacy of tace combined with lenvatinib and pd-1 inhibitor as first-line therapy.

Eligibility criteria:
inclusion criteria: 1. diagnosis of primary hcc, confirmed histologically or clinically according to the criteria of the american association for the study of liver diseases; 2. presence of hemostasis in the enhanced ct scan; 3. integrity of the tumor is disrupted and there is hematoma around the liver; 4. receipt of lenvatinib and pd-1 inhibitor as the first-line systemic therapy; 5. transarterial artery chemoembolization (tace) as local therapy; 6. classified as child-pugh class a or b and having an eastern cooperative oncology group (ecog) performance status of 0 or 2; 7. no history of other malignancies. 8. life expectancy more than 3 months; 9. agreed to participated in this clinical trial; 10. hemameba ≥3.0 x109/l, neutrophil ≥1.5x109/l, hemoglobin≥10.0 g/l, platelet≥100x 109/l, alt; ast; bilirubin ≤1.5-fold normal, gfr≥60ml/min. exclusion criteria: 1. recurrent hcc; 2. non-ruptured hcc; 3. lenvatinib and pd-1 inhibitor treated with as second systemic therapy; 4. age \ 75 years; 5. hcc with more than five metastases; 6. history of hepatic encephalopathy and gastrointestinal bleeding 7. life expectancy less than 3 months.

Keywords: ruptured hepatocellular carcinoma tace lenvatinib tislelizumab sintilimab camrelizumab
virtual reality exposure therapy in agoraphobic participants

Conditions: Panic Disorder; Agoraphobia

Summary: virtual reality exposure therapy (vret) is an effective treatment for anxiety disorders, particularly for specific phobias as fear of heights and fear of flying (e.g. powers \& emmelkamp, 2008). recent technological advances (e.g. more realistic avatars) make research into the efficacy of vret for participants with elevated agoraphobic symptoms desirable. therefore, the aim of the present research proposal is to investigate the comparative efficacy of: 1. enhanced vret making use of the latest avatar technology with 2. exposure in vivo in agoraphobic participants 3. wait-list control.


Eligibility criteria:
inclusion criteria: * a full diagnosis of panic disorder with agoraphobia according to the dsm-iv * between the ages of 18-65 years * sufficient fluency in dutch to complete treatment and research protocol exclusion criteria: * presence of medical condition, assessed by self-report questionnaires at the intake (i.e., pregnancy, seizure disorder, pacemaker) * current use of beta-blockers * current use of tranquilizers (benzodiazepines) * unstable psychotropic medication * substance dependence * psychosis * depression with suicidal ideation * posttraumatic stress disorder * dementia or other severe cognitive impairment * bipolar disorder * borderline personality disorder * anti-social personality disorder

Keywords: panic disorder and agoraphobia virtual reality exposure therapy
the staying well study: an open trial of mindfulness-based cognitive therapy for the prevention of perinatal depression

Conditions: Pregnancy; Depression; Postpartum Depression

Summary: pregnant women with histories of depression are at high risk of depressive relapse during the perinatal period, and options for relapse prevention are limited. mindfulness-based cognitive therapy (mbct) has strong evidence among general populations but has not been studied among at risk pregnant women. this study is the first phase of a multi-phase project adapting mbct for perinatal women (mbct-pd). it is being conducted in a collaboration between the university of colorado, emory university, and kaiser permanente at colorado and georgia.

mindfulness-based cognitive therapy (mbct) represents one of the most important recent developments in the effort to prevent recurrent depression. explicitly designed to modify core underlying vulnerability factors among recovered individuals with histories of depression, mbct may have high applicability to the prevention of perinatal depression (pd). during this phase of the project the investigators will employ an iterative process to develop, within routine obstetric clinical settings, the mbct-pd program across a two-center open trial of pregnant women at high risk of perinatal depression. during this phase, the investigators will modify the standard mbct approach to be sensitive and specific to women at high risk of perinatal depressive relapse or recurrence based on previous history of depression and will address the following aims: * specific aim 1: to examine the feasibility of mbct-pd with respect to identification and enrollment of women at-risk of perinatal depression based on a history of depression. * specific aim 2: to examine the engagement of women with the mbct-pd approach with respect to retention, completion of daily practice assignments, and satisfaction * specific aim 3: to examine the clinical outcomes including change in depression symptom levels and rates of relapse/recurrence over the course of the intervention and through a 6-month postpartum follow-up.

Eligibility criteria:
inclusion criteria: * pregnant up to 32 weeks gestation * meeting criteria for prior depression * failure to meet criteria for a diagnosis of mdd in the last two months * available for group intervention scheduled meetings exclusion criteria: * presence of schizophrenia or schizoaffective disorder * presence of bipolar disorder or current psychosis * presence of organic mental disorder or pervasive developmental delay * presence of current eating disorder * presence of current substance abuse or dependence * presence of antisocial, borderline, or schizotypal personality disorder * presence of imminent suicide or homicide risk * presence of any other axis i or ii disorders that necessitate priority treatment not provided by the study protocol * women with any medical conditions that would preclude participation, including high-risk pregnancy

Keywords: depression mindfulness pregnancy prevention cognitive behavioral therapy
health education approach to lung screening

Conditions: Lung Cancer

Summary: evaluate the impact of the patient navigation program on the proportion of patients who complete lung cancer screening (lcs), defined as undergoing a low dose computed tomography (ldct)

this is a single-arm study of a patient navigation intervention to increase access to lung cancer screening (lcs).

Eligibility criteria:
inclusion criteria: * meets current uspstf guidelines for lung cancer screening (lcs) * 20 pack-year smoking history note: a pack-year is a way of calculating how much a person has smoked in their lifetime. one pack-year is the equivalent of smoking an average of 20 cigarettes-1 pack-per day for a year. * currently smokes or has quit smoking within the past 15 years * identifies as black or african-american note: both hispanic/latino and non-hispanic/latino patients are eligible as long as they also identify as black or african-american (eg, afro-latino). * willing to complete all navigation-related study activities * able to understand and the willingness to sign a written informed consent document exclusion criteria: a patient who meets any of the following exclusion criteria is ineligible to participate in the study: * known history of cancer (except squamous cell skin cancer), or coughing up blood in the past 5 years, as reported by the individual * has undergone a previous lung cancer screening * inability to speak english * medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Keywords: lung cancer screening
emotion and cognitive function and brain imaging change in hd patients

Conditions: Kidney Failure, Chronic; Cognitive Dysfunction; Magnetic Resonance Imaging

Summary: 1. observe the influence of entering hemodialysis treatment on the emotional and cognitive functions of esrd patients. 2. observe the influence of entering hemodialysis treatment on the brain structure imaging of esrd patients. 3. analyze and study the relevant clinical risk factors of the above-mentioned effects, and find targets for therapeutic intervention.

select uremic patients and maintenance hemodialysis patients admitted to the central dialysis room of beijing friendship hospital, capital medical university from 2021, to collect and sort out the demographic characteristics of the patients: gender, age, clinical characteristics: primary disease, complications and complications, body mass index (bmi), residual renal function, etc., clinical examination indicators: hemoglobin, blood calcium, blood phosphorus, blood pth, blood albumin, urr, etc., hemodialysis treatment parameters: dialysis mode, dialyzer model, vascular access , blood flow, etc., record the patient's emotional and cognitive function status, various clinical indicators and changes in the patient's quality of life before and after the start of treatment, and use multimodal magnetic resonance neuroimaging research sequences to analyze the changes in the patient's brain structure and function.

Eligibility criteria:
inclusion criteria: * patients who are new to hemodialysis treatment, and those who are on regular hemodialysis treatment for ≥6 months. * age ≥ 18 years old. exclusion criteria: * there was already a severe central nervous system disease before dialysis. * hearing and visual impairment cannot communicate or cooperate. * mental illness and incapacity. * the magnetic resonance examination could not be completed for various reasons. * life expectancy with serious diseases is less than 6 months.
validity of the spanish version of subjective well-being under neuroleptics scale (swn-k) in patients with schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder

Summary: observational, short-term prospective, multicenter study to assess psychometric properties of the spanish version of swn-k scale in patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder (dsm-iv tr criteria) * stabilized out-patients * under treatment with an oral antipsychotic drug exclusion criteria: * administration of a depot antipsychotic drug * participation in another clinical trial within 4 weeks prior to enrolment into this study

Keywords: schizophrenia subjective well-being psychometric validation
safety, tolerability, pharmacokinetics and pharmacodynamics of anx005 in participants with warm autoimmune hemolytic anemia (waiha)

Conditions: Warm Autoimmune Hemolytic Anemia (wAIHA)

Summary: this study will evaluate the safety and tolerability of anx005 in participants with warm autoimmune hemolytic anemia (waiha).

after being informed of study details and potential risks, all participants who provide written informed consent will undergo an up to 6-week screening period to determine eligibility. participants who meet the eligibility criteria will receive two once-weekly intravenous (iv) infusions of anx005. participants will return to the clinic weekly through week 10 for study assessments. the total duration of individual participation in this study will be up to 16 weeks.

Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating female ≥18 years of age (no maximum age). * diagnosis of waiha at least 3 months prior to screening with a direct antiglobulin test (dat) ≥1 positive for immunoglobulin g (igg)±c3, or a diagnosis of mixed autoimmune hemolytic anemia (aiha) that is dat positive for both igg and c3, with a presence of a cold antibody with a thermal amplitude ≥30ºcelcius. * hemoglobin (hgb) level ≤10.0 grams/deciliter (pre-transfusion). * evidence of classical complement pathway activation. * evidence of active hemolysis. * stable use of glucocorticoids and immunosuppressants are permitted. * vaccinations against encapsulated bacterial organisms within 5 years prior to screening or participant must be willing to receive prophylaxis against infections with encapsulated bacteria via vaccination and/or the use of prophylactic antibiotics in accordance with local standards of practice and/or guidelines. exclusion criteria: * elevated aspartate aminotransferase or alanine aminotransferase levels \>2.5 times the upper limit of normal. * platelet count \<30 x 10\^9/liter. * history of cold agglutinin disease. * history of solid organ, bone marrow, or stem cell transplantation. * history of splenectomy within the 3 months prior to screening. * received rituximab or other anti-cd20 monoclonal antibody \<3 months prior to screening. * intravenous immunoglobulin (ivig) treatment within 3 months prior to screening or plasmapheresis or immunoadsorption treatment within 60 days prior to screening. * clinically significant, recent, or ongoing illness or medical condition, including coexistent autoimmune disorder, malignancy, hiv, hepatitis b virus, and hepatitis c virus. * history of meningitis or septicemia within the past 2 years. * treatment with an investigational therapeutic agent within 30 days prior to screening. * hypersensitivity to any drug product or excipients used in this study or to previous iv medication administration. * body weight less than 50 kilograms (kg) or greater than 100 kg

Keywords: aiha c1q complement rbc lysis
effect of radiofrequency ablation in patients with ventricular arrhythmia undergoing cabg

Conditions: MI Related Malignant Ventricular Arrhythmia

Summary: patients with myocardial infarction related potential malignant ventricular arrhythmia have high risk of sudden death. the aim of this clinical trial is evaluating therapeutic efficacy of unipolar or bipolar radiofrequency ablation in coronary artery bypass grafts (cabg) surgery, which can reduce myocardial ischemia and block reentry circuits of ventricular arrhythmia at the same time. the observation indexes include the morbidity of potential malignant ventricular arrhythmia and major adverse cardiovascular events in mid-long-term after cabg surgery.


Eligibility criteria:
inclusion criteria: * the patients have been receiving coronary artery bypass grafts from 2015.1-2017.12 * the patients had old myocardial infarction related potential malignant ventricular arrhythmia * anti-arrhythmic drug treatment is invalid * all enrolled patients must being signed the informed consent exclusion criteria: * severe heart failure( ejection fraction under 35%) * patients with acute myocardial infarction * patients with icd implanted

Keywords: myocardial infarction ventricular arrhythmia radiofrequency ablation coronary artery bypass grafts
visceral somatization and low back pain.

Conditions: Lumbar Strain

Summary: this study aims to verify the significance of the inclusion of procedures of a comprehensive therapeutic approach according to eastern techniques to classical physiotherapy and to find out whether these eastern techniques can contribute to the enrichment of standard physiotherapy. according to tcm and ayurveda, another goal is to develop appropriate regimen measures to create a yoga regimen suitable for patients who have renal and bladder dysfunction according to tcm and whose main common symptom is chronic non-specific low back pain. the study is based upon comparing a four-week physiotherapy program according to the physician's indication and a physiotherapy program enriched with compiled regimen measures and yoga exercises in selected probands.

two groups of probands were used - an experimental and control group. there were 6 probands in each group. the four-week therapy effect, which took place twice a week for 60 minutes, was compared. the control group received physiotherapy, as indicated by the physician. according to tcm and ayurveda, the experimental group underwent physiotherapy as indicated by a doctor enriched with yoga exercises and regime measures. it was asked to perform yoga exercises daily at home. the therapy's effect was evaluated using the short-form-36 health-related quality of life questionnaire (hrqol), the vas scale of pain intensity, the number of responses in the anamnestic questionnaire the author compiled the kinesiological analysis.

Eligibility criteria:
inclusion criteria: * more than half of the answers in the anamnestic questionnaire (n ≥ 14) * more than half of the answers in the kinesiological analysis (n ≥ 7) * lower back pain lasting longer than 12 weeks * degree of pain ≥ 3 on a visual analog scale exclusion criteria: * neurological or other structural cause of lower back or other pain key symptoms * serious systemic diseases (dm, heart or cancer) * contraindications to movements of the spine and other root joints of the body in full scope * pregnancy * simultaneous completion of another physiotherapeutic intervention, yoga exercise or treatment according to tcm * use of analgesics, antiphlogistics or muscle relaxants during therapy

Keywords: physiotherapy low back pain chinese medicine yoga
predictive value of analysing tissue from patients with metastatic pancreatic cancer for drug sensitivity

Conditions: Metastatic Pancreatic Cancer

Summary: it will be investigated whether it is possible to predict the effect or lack of effect of first-line treatment by analysing cancer cells from the individual patient receiving standard first line treatment. also, the feasibility of selecting second-line therapy based on pre-treatment biopsies will be investigated. cells from pancreatic cancer will be grown in the laboratory to form small, circulating tumors and adjacent tissue, so called tumoroids. the tumoroids will then be exposed to different pre-specified anticancer drugs to hopefully reveal sensitivity or lack of sensitivity in the specific patient.


Eligibility criteria:
inclusion criteria: * non-resectable pancreatic cancer * biopsy proven adenocarcinoma compatible with pancreatic origin (primary tumor or metastasis) * if only biopsy from metastasis can be obtained, the patient must have a previously resected or image proven tumor of the pancreas * deemed non-resectable at a multidisciplinary conference * candidate to standard systemic therapy, defined as one of * gemcitabine monotherapy, * gemcitabine and nab-paclitaxel combination, * gemcitabine and capecitabine combination, * 5-fluorouracil, oxaliplatin and irinotecan combination (folfirinox), or * new standard treatments approved by the multidisciplinary cancer group 'danish pancreatic cancer group' in the inclusion period. * measurable disease according to recist 1.1 * ecog performance status 0-2 * age at least 18 years * adequate bone marrow, liver and renal function allowing systemic chemotherapy * absolute neutrophil count ≥1.5x10\^9/l and thrombocytes ≥ 100x10\^9/l * bilirubin ≤ 3 x upper normal value and alanine aminotransferase ≤ 5 x upper normal value * calculated or measured renal glomerular filtration rate at least 30 ml/min * contraception for fertile women and for male patients with a fertile partner. intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable * written and orally informed consent exclusion criteria: * potentially resectable disease * incapacity, frailty, disability, or comorbidity to a degree that according to the investigator is not compatible with participation in the protocol * other active malignant disease requiring therapy * other systemic anti-cancer therapy (palliative radiotherapy is allowed) * pregnant (positive pregnancy test) or breast feeding women